Childhood Acute Lymphoblastic Leukemia
Last Posted: Aug 20, 2021
- Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia
DS Mangum et al, JAMA Oncology, August 19, 2021
- Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment.
Pavlovic Sonja et al. Genes 2019 Mar 10(3)
- Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing.
Ishida Hisashi et al. Annals of hematology 2018 Nov
- Influence of IL15 gene variations on the clinical features, treatment response and risk of developing childhood acute lymphoblastic leukemia in Latvian population.
Rots Dmitrijs et al. Pediatric hematology and oncology 2018 Feb 35(1) 37-44
- Pharmacogenomics in acute lymphoblastic leukemia.
Lee Shawn H R et al. Best practice & research. Clinical haematology 2017 Sep 30(3) 229-236
- Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou Despina et al. Annals of hematology 2018 Mar
- Impact of CYP1A1, GSTP1 and XRCC1 genes polymorphisms on toxicity and response to chemotherapy in childhood acute lymphoblastic leukemia.
Abo-Bakr Asmaa et al. Journal of the Egyptian National Cancer Institute 2017 Aug
- Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf Barthelemy, et al. JAMA 2015 2 0. (8) 815-23
- Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
Pui Ching-Hon et al. Front Med 2015 Mar (1) 1-9
- Pharmacogenetics of childhood acute lymphoblastic leukemia.
Lopez-Lopez Elixabet et al. Pharmacogenomics 2014 Jul (10) 1383-98
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.